Skip to main content
Log in

The need of a new and more physiological preclinical model for Parkinson’s disease

  • Letters and comments
  • Published:
Cellular and Molecular Life Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Lindholm D, Mäkelä J, Di Liberto V, Mudò G, Belluardo N, Eriksson O, Saarma M. (2015) Current disease modifying approaches to treat Parkinson’s disease. Cell Mol Life Sci. 2015 Nov 30 [Epub ahead of print]

  2. Brotchie J, Jenner P (2011) New approaches to therapy. Int Rev Neurobiol 98:123–150. doi:10.1016/B978-0-12-381328-2.00005-5

    Article  CAS  PubMed  Google Scholar 

  3. Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA (2014) Protective and toxic roles of dopamine in Parkinson’s disease. J Neurochem 129:898–915. doi:10.1111/jnc.12686

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Juan Segura-Aguilar.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Segura-Aguilar, J., Paris, I. & Muñoz, P. The need of a new and more physiological preclinical model for Parkinson’s disease. Cell. Mol. Life Sci. 73, 1381–1382 (2016). https://doi.org/10.1007/s00018-016-2140-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-016-2140-2

Keywords

Navigation